We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A U.S. division of India’s Ranbaxy Laboratories will introduce its generic versions of Sciele Pharma’s Robinul and Robinul Forte by the end of the year, after receiving FDA approval for the products.